PDCD1 and non-small cell lung carcinoma: Studies suggesting a link between human gut microbiota and clinical responses to anti–PD-1/PD-L1 treatment in diseases such as melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and urothelial cancers have gained recognition in the recent years [13,23] (Table 1).